CADL - CONSENSUS CO - Candel Therapeutics

Candel Therapeutics (CADL) is developing viral tumor therapies, relying on long-term treatment courses to ensure stable revenue. The company is implementing ESG standards by reducing laboratory waste and adhering to bioethics. Anticipation of the new vaccine test results at the current price of 21.81 confirms the price action chart on GURU.Markets, which has already priced in clinical stage risks.

The lack of revenue and high capital burn rate associated with the development of oncolytic vaccines at Candel Therapeutics (CADL) make the stock price extremely sensitive to clinical trial results. The history of expert consensus estimates reflects a weighted average target price calculated by investment banks via discounted cash flow analysis, where any sharp fluctuations in the curve signal a revision of the market's fundamental expectations regarding the success of the drugs.